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Breast cancer is one of the most prevalent types of malignant tumors in the world,
resulting in a high incidence of death. The development of new molecules and
technologies aiming to apply more effective and safer therapy strategies has been
intensively explored to overcome this situation. The association of nanoparticles with
known antitumor compounds (including plant-derived molecules such as curcumin) has
been considered an effective approach to enhance tumor growth suppression and reduce
adverse effects. Therefore, the objective of this systematic review was to summarize
published data regarding evaluations about efficacy and toxicity of curcumin nanoparticles
(Cur-NPs) in in vivomodels of breast cancer. The search was carried out in the databases:
CINAHL, Cochrane, LILACS, Embase, FSTA, MEDLINE, ProQuest, BSV regional portal,
PubMed, ScienceDirect, Scopus, and Web of Science. Studies that evaluated tumor
growth in in vivo models of breast cancer and showed outcomes related to Cur-NP
treatment (without association with other antitumor molecules) were included. Of the 528
initially gathered studies, 26 met the inclusion criteria. These studies showed that a wide
variety of NP platforms have been used to deliver curcumin (e.g., micelles, polymeric, lipid-
based, metallic). Attachment of poly(ethylene glycol) chains (PEG) and active targeting
moieties were also evaluated. Cur-NPs significantly reduced tumor volume/weight,
inhibited cancer cell proliferation, and increased tumor apoptosis and necrosis.
Decreases in cancer stem cell population and angiogenesis were also reported. All the
studies that evaluated toxicity considered Cur-NP treatment to be safe regarding
hematological/biochemical markers, damage to major organs, and/or weight loss.
These effects were observed in different in vivo models of breast cancer (e.g., estrogenMarch 2021 | Volume 11 | Article 6129031
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Frontiers in Oncology | www.frontiersin.orgreceptor-positive, triple-negative, chemically induced) showing better outcomes when
compared to treatments with free curcumin or negative controls. This systematic review
supports the proposal that Cur-NP is an effective and safe therapeutic approach in in vivo
models of breast cancer, reinforcing the currently available evidence that it should be
further analyzed in clinical trials for breast cancer treatments.Keywords: breast cancer, nanoparticle, curcumin, apoptosis, antitumor, toxicity, in vivo, systematic reviewINTRODUCTION
Among women, breast cancer is the most prevalent cancer
worldwide, with 2.1 million cases reported in 2018 (with an
annual increase of 3.1%) and more than 620,000 deaths per year
(1, 2). Breast cancer is divided into five major intrinsic molecular
subtypes: luminal A-like (60–70%), luminal B-like human
epidermal growth factor receptor-type 2 negative (HER2–) (10–
20%), HER2-enriched (non-luminal) and luminal B-like HER2+
(13–15%), and triple-negative (10–15%) (1). Early diagnosis of
breast cancer raises the chances of total recuperation of patients,
and the treatment concept is decided based on several criteria such
as subtype and grade (3). Chemotherapy and endocrine therapy
are typical systemic therapies in non-metastatic breast cancer.2
They can be associated with local therapy like surgery and
radiation (3). In most cases, metastatic breast cancer remains
incurable and therapy aims to prolong life and alleviate symptoms
(3). However, these conventional treatments present some
limitations, like resistance to chemotherapy or endocrine
therapy, and some adverse effects (4). Thus, alternative
treatments must be investigated to improve the recovery of
breast cancer patients, reduce adverse effects, and circumvent
therapy resistance.
Natural products are considered as promising alternatives for
the development of new antitumor drugs (5, 6). Curcumin, or
diferuloylmethane, is a yellow pigment extracted from the
rhizomes of Curcuma longa Linn, also known as turmeric. It is
the most abundant polyphenol and curcuminoid present in theGRAPHICAL ABSTRACT |March 2021 | Volume 11 | Article 612903
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medicine, curcumin also interests conventional medicine by
demonstrating antioxidant and anti-inflammatory activities (7).
Its anti-cancer effect was reported for the first time in 1985, by
Kuttan and co-workers, in cells and animal models of lymphoma
(8). In breast cancer, curcumin inhibits cell proliferation, induces
apoptosis (5) and acts as a potent antiangiogenic, anti-invasive,
and anti-metastatic agent in vitro and in vivo (9). Curcumin also
demonstrated the capacity to reverse chemotherapeutic resistance
in doxorubicin-resistant breast cancer cells (MCF-7/DOX and
MDA-MB-231/DOX) (10). Moreover, curcumin led to the
downregulation of aldehyde dehydrogenase-1, and p-
glycoprotein-mediated multidrug resistance gene expression,
increasing sensitivity of breast cancer cells (MCF-7) to paclitaxel
(11). However, the therapeutic application of curcumin is limited
due to its poor water solubility and low bioavailability. Thus, some
studies have investigated the use of nanoparticles (NPs) to deliver
curcumin to breast cancer cells and enhance its bioavailability and
efficacy (12).
Nanotechnology is a strong alternative tool to improve
application of hydrophobic molecules. The use of NPs increases
the stability and bioavailability of antitumor compounds, reduces
therapeutic doses, andminimizes possible adverse effects (13). Several
types of NPs can be used as drug delivery systems, such as polymer
NPs, liposomes, nanoemulsions, metal NPs, micelles, solid lipid NPs,
dendrimers, nanospheres, and nanocapsules (14). These NPs can also
be associated with other molecules like aptamers, antibodies, or
polymers as active targeting moieties. This surface modification can
improve the specificity of NPs to tumor cells, facilitate their
interaction, and, consequently, increase antitumor effects (13).
At present, there are several clinical trials in which curcumin
has been evaluated, mainly after oral administration regimens, in
breast cancer patients (e.g., NCT03980509, NCT01042938,
NCT03847623, NCT03865992, NCT01740323, NCT01975363,
NCT02556632, NCT01246973, NCT03482401) (15). So far, only
one clinical trial using intravenous administration of a curcumin
water-soluble formulation (CUC-1®) in combination with
paclitaxel in breast cancer patients has been registered
(NCT03072992) (15).
A substantial number of studies have been published
describing the activity of Cur-NPs in in vivo models of breast
cancer. Nevertheless, to the best of our knowledge, a systematic
review on this subject has not been published yet. Therefore,
considering the importance of in vivo studies and their
clinical translation, the aim of this systematic review was to
summarize published data regarding evaluations about efficacy
and toxicity of Cur-NPs in in vivo models of breast cancer, as
well as showing evidence for the potential of this therapeutic
approach for clinical trial investigations. Although several works
describing interesting data regarding the combination of curcumin
with chemotherapeutic drugs have been published (16, 17), the
present systematic review was performed to cover studies evaluating
curcumin as the active antitumor agent, associated with NPs, to
understand better the effects on breast tumor progression of
curcumin itself and the advantages/limitations of using NPs as its
dug carrier.Frontiers in Oncology | www.frontiersin.org 3MATERIALS AND METHODS
Protocol and Registration
The present study was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines (18). The protocol for this systematic
review was registered in the International Prospective Register




This systematic review based the inclusion criteria on the PICOS
(Population, Intervention, Comparison, Outcome, and Study
Design) approach (20). We considered studies which evaluated
the efficacy and toxicity (O) of Cur-NPs (I) compared with free
curcumin and/or negative control (C) on in vivomodels of breast
cancer in mice or rats (P).
Exclusion Criteria
Studies were excluded for the following reasons: i) reviews,
letters, personal opinions, book chapters, and conference
abstracts; ii) in vitro studies and clinical trials; iii) use of only
free curcumin or curcumin derivatives; iv) other types of cancer;
v) use of Cur-NPs associated with other antitumor compounds;
vi) full paper copy not available; vii) low quality.
Information Sources and Search Strategy
Individual search strategies were designed for each of the
following bibliographic databases: CINAHL, Cochrane,
LILACS, Embase, FSTA, MEDLINE, ProQuest, BSV regional
portal, PubMed, ScienceDirect, Scopus, and Web of Science
(Table S1). The search on databases was performed on August
10 and 11, 2020, with no time restriction. Duplicated references
were removed by reference manager software (Mendeley®). There
were no restrictions on language and period of publication.
Study Selection
The articles were selected in two phases: screening of titles and
abstracts (phase 1) and full text reading (phase 2). In phase 1, two
authors (A.S.O. and V.R.P.S) reviewed titles and abstracts of all
references identified in the electronic databases and selected articles
that seemed to meet the inclusion criteria. In phase 2, six pairs of
authors (A.S.O and V.R.P.S.; L.R.A and G.J.F; W.O.P and A.C.P;
J.V.O and M.P.G; M.S and G.F.G; P.M.C. and G.A.J.) were formed
to independently analyze the full text of articles selected in phase 1
and exclude studies that did not meet the inclusion criteria (Table
S2). A third author was consulted if disagreements between the two
initial evaluators were not solved by consensus. Extraction of
relevant data was done in all included studies to identify animal
model, intervention (treatment regimen, dose, route, and NP
platform) and outcomes (antitumoral activity and toxicity analysis).Risks of Bias and Quality in Individual Studies
The quality of the articles included was estimated by applying the
10-question form from SYRCLE’s RoB Toll (Table S3) (21), toMarch 2021 | Volume 11 | Article 612903
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and other bias. The items were answered in each study by two
reviewers individually and the disagreements were resolved by a
third reviewer. YES answers indicated low risk of bias, NO
indicated high risk of bias, and UNCLEAR indicated it was not
possible to assign bias. As a secondary analysis, the quality of the
studies was also assessed through 15 questions related to the
methodology (Table S4) [based and adapted from the ARRIVE
Guideline (22)], and measurement of the outcomes, which were
raised by the reviewers and applied in order to classify the studies
according to the percentage of YES responses to the criteria
raised, being considered as high quality studies with > 70%,
moderate quality with 50–69%, and low quality < 49%.RESULTS
Study Selection
Research on breast cancer has significantly increased. This can be
observed, for example, when using the search string “(TITLE-
ABS-KEY ((“Breast Cancer” OR “Breast Neoplasm” OR
“Mammary Cancer” OR “Malignant Neoplasm of Breast” OR
(“Mammary Carcinoma” ANDHuman) OR “Breast Carcinoma”
OR “Cancer of Breast”)))”, on September 27, 2020, in the
scientific database Scopus (23), for example, 530,186 document
results were found. Of these, some of the regions/countries that
published the most were: United States > China > United
Kingdom > Germany > Italy > France > Japan > Canada >
Australia > India, where the United States published 33.53% and
China 8.32% of the studies.
When filtering these results with the search string “(TITLE-
ABS-KEY ((“Breast Cancer” OR “Breast Neoplasm” OR
“Mammary Cancer” OR “Malignant Neoplasm of Breast” ORFrontiers in Oncology | www.frontiersin.org 4(“Mammary Carcinoma” AND human) OR “Breast Carcinoma”
OR “Cancer of Breast”) AND (curcumin OR “Turmeric Yellow”
OR (yellow AND turmeric) OR diferuloylmethane)) AND
TITLE-ABS KEY ((nanoparticles OR nanoparticle OR nanogels
OR “Nanocomposite Gels” OR “Nanocomposite Gel” OR
nanocapsule OR nanocapsules OR nanoemulsion OR micelle
OR micelles OR liposome OR liposomal))),” in order to find
studies that have specifically investigated curcumin associated
with NPs, 402 documents were obtained (Figure 1). The
countries/regions that most published on “breast cancer AND
curcumin AND nanotechnology” were India, United States, China,
Iran, Italy, among others, according to the Scopus database.
When conducting a bibliometric study of the results obtained
in the last search in the Scopus database, using the VOSviewer
1.6.15 program (24), 159 terms were obtained, when establishing
at least 10 co-occurrences and “binary count” (presence or
absence in each study) configurations. Figure 2 shows the
interrelation of three clusters among the most recurrent terms
used, where therapy, cytotoxicity, anticancer activity, and
apoptosis were among the terms of greatest interest to the
scientific community regarding the evaluated topic.
Data presented in Figures 1 and 2 were obtained using only
the Scopus database in order to give a general overview of the
topics discussed herein. However, in the present systematic
review, a total of 528 studies were identified from different
databases (57 from ScienceDirect; 35 from LILACS; 113 from
Embase; 52 fromMEDLINE; 60 from Portal Regional da BSV; 55
from PubMed; 41 fromWeb of Science; 112 from Scopus; 1 from
CINAHL, 1 from FSTA, and 1 from ProQuest) (Table S1). After
duplicate removal, 320 studies remained and an evaluation of
“title and abstract” resulted in the exclusion of 244 studies. The
remaining 76 articles were analyzed by full-text review. This
process led to exclusion of 50 articles according to exclusion

























FIGURE 1 | Number of publications listed in Scopus database with MeSH terms for curcumin nanoparticles and breast cancer. Data obtained on September 27, 2020.March 2021 | Volume 11 | Article 612903
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flowchart detailing this process is shown in Figure 3.
Characteristics of the Included Studies
All included studies are research articles that evaluated
antitumoral activity of Cur-NPs in in vivo models of breast
cancer. The main characteristics of the studies are summarized in
Table 1.
The studies were conducted in several countries: China (n =
13); India (n = 6); Bahrain (n = 1); Iran (n = 4); Italy (n = 1); US
(n = 1); Republic of Korea (n = 1), and all of them were published
from 2014 to 2020 in the English language.
Cur-NPs used in the included studies were mainly described
by hydrodynamic diameter (HD) (n=26), polydispersity index
(PdI) (n=17), and zeta potential (n=21) through dynamic light
scattering and electrophoretic mobility. Some studies assessed
NPs’ size and/or morphology by transmission electron
microscopy (TEM) and/or scanning electron microscopy
(SEM). Curcumin encapsulation efficiency (EE%) was
evaluated mostly by high-performance liquid chromatography
(HPLC) (n=18).
All in vivo studies followed the progression of tumor volume
during the experimental period by measuring tumor small/large
diameters or width/length and calculating the final volumes with
mathematical formulas. Studies also assessed tumor weight
(n=16); survival time (n=3); tumoral stem cells through flow
cytometry (n=2); ratio of M1/M2 macrophages through RT-PCR
(n=1); apoptosis (n=8), necrosis (n=5), proliferation (n=4),
angiogenesis (n=5), cell density (n=4), inflammatory response
in the tumor (n=1), and metastasis (n=1) through classical
histology (HE) and immunohistochemistry. Regarding toxicity
analysis, 21 studies used at least one parameter of evaluation.
Studies assessed weight loss (n=15); damage of major organs
through classical histology (HE) (n=9); food intake/behaviorFrontiers in Oncology | www.frontiersin.org 5(n=1); inflammatory cytokine levels (n=1) through ELISA;
hemolysis (n=2) through absorbance; and hematological
(n=3) and biochemical parameters (n=6) through animal blood
counter and commercial kits.
Quality and Risk of Bias in
Individual Studies
When analyzed by questions based on ARRIVE guidelines, as
seen in Table 2, 23 studies were graded as of high quality and 3 as
of moderate quality. Most studies clearly reported the
encapsulation methods of curcumin (n=24) and investigated
characteristics of NPs (n=23). Animal models were considered
adequate in all studies and ethical committee approval was
clearly reported in 18 studies. Six studies did not clearly report
ethical approval and two other articles did not mention this
criterion. Furthermore, animal conditions during the experiment
were not clearly described in 13 studies. The study design of
anticancer activity was well executed in most studies and some
articles clearly mentioned time of treatment (n=25), route of
administration (n=22), dose of curcumin (n=25), and presence
of control groups (n=25). Nevertheless, only 15 studies
investigated anticancer activity of free curcumin to compare
with the Cur-NP effect. Additionally, a toxicity assay was
performed in 21 studies. Lastly, statistical models were
considered as unclear in all studies due to lack of information.
Risk of bias assessment based on SYRCLEs’ RoB guidelines of
all included studies is summarized in Table 3. Criteria were
considered unclear when they were not clearly reported or gave
incomplete information. Most studies did not clearly describe
information on allocation, randomization, and blinding, which is
required for quality assessment. Animals were not randomly
housed during the experiment in two studies. Additionally, three
studies did not adequately address incomplete outcome data. In
parallel, the experimental groups were considered similar in 18FIGURE 2 | Bibliometric study of publications listed in Scopus database, with MeSH terms for curcumin nanoparticles and breast cancer, using the VOSviewer
program (24), in “title and abstract”, with at least 10 co-occurrences and binary count configurations. Data obtained on September 27, 2020.March 2021 | Volume 11 | Article 612903
TABLE 1 | Summary of descriptive characteristics of the included studies.
Outcomes
Antitumor activity Toxicity analysis
ur-NP ↓TV (58.9%); free Cur ↓TV
%); p<0.001
(ND)
ur-NP ↓TV (~60%) and ↓ TW




ur-NP ↑TNC and ↑TAP No WL;
hematological
indices: ~ control
ur-NP ↓CD44+ CD133+ cancer
cells
p<0.05
ur-NP-FA ↓TV (~51%); free Cur:
TV; p<0.006
(ND)
ur-NP-FA ↓TW (~44%); free Cur:
V↓; p<0.05




























































Animal modela Treatment regimenb Dose; route Nanostructure platform
Shukla et al. (25)/India Balb/c mice/n = 3/ Ten days from tumor
inoculation;
100 mg/kg; Lipid based CPC-SNEDDS NPs (Phospholipid,
castor oil, Tween 80, PEG 400);
1) C
(29.
4T1/mouse/ Daily for 28 days Oral HD: 83.27 nm/PDI: 0.151;
(1 x 106 cells)/ - Free Cur vehicle: ZP: −16 mV/EE: 29.1%
subcutaneously on back
skin
gum acacia (1%, w/v).





BT-549/human/ Fourteen days at every 2 days Intratumoral HD: 3.86 nm/PDI: 0.125; 2) C




Mahalunkar et al. (27)/
India, Germany, and
Norway
Balb/c mice/n = 6/ First day of treatment: (NM) 10 mg/kg; Metal gold NPs (CurAu-PVP) with folic acid (FA)
(HAuCl4 and PVP polymer).
1) C
no ↓
4T1/mouse/ Twice a week for 2 weeks Intratumoral HD: 358.7 nm/PDI: 0.6 2) C
no T
(1 x 105 cells)/ - Free Cur vehicle: (NM) ZP: −12.5 mV/EE: (NM)
Mammary fat pad
Alizadeh et al. (28)/Iran Balb/c mice/n = 8/ 14 days after tumor induction; Dose: (NM); Micelles/polymersomes NPs (PNP) [monomethoxy-





Daily for 24 days Intraperitoneal HD: 99.44 nm/PDI: 0.182; 2) C
↓PR
Pieces < 0.3 cm3/ ZP: −29.3 mV mV/EE: 64%
Subcutaneous on the
left flank
Jung et al. (29)/
Republic of Korea




MDA-MB-468/human/ Three times a week; total of
eight injections
Intraperitoneal Cur-NP and EGF-Cur-NP: HD: 248.9 and 229.3 nm/
PDI: 0.170 and 0.200, respectively
(5 x 106 cells)/ Cur-NP and EGF-Cur-NP: ZP: −3.6 and −1.73 mV,
respectively/EE: (NM)
Right shoulder
Wang et al. (30)/China Nuke mice/n = (NM)/ Two months after tumor
induction;
1 × 10−3 M; Polymeric NPs (MPEG-PCL); 1) C
(~49
MDA-MB-231/human/ Daily for 2 weeks Intravenous HD: 139 nm/PDI: (NM); 2) C
(1.5 x 106 cells)/ - Free Cur vehicle: (NM) ZP and EE: (NM)
Subcutaneous5
n
TABLE 1 | Continued
Outcomes
Antitumor activity Toxicity analysis






) Cur-NP ↓TW (~74%); Cur-NP-FA
TW (~85%); p<0.05
p<0.05
) Cur-NP and Cur-NP-FA ↓ tumor cell
ensity
) Cur-NP ↓TV (~20%); Free Cur: ↓TV
16%); p<0.05
(ND)
) Cur-NP ↓TV (~28.0%); p<0.05 No damage in
major organs;
) Cur-NP ↓TW (~22.5%); p<0.05 No WL
) Cur-NP ↓breast cancer stem cells
62%); p<0.05
p<0.05
) Cur-NP-FA↓TV (~86%); p<0.05 No damage in
major organs;
) Cur-NP-FA ↓TW (~76%); p<0.05 No WL
) Cur-NP-FA ↑ ST and ↓ metastasis;
<0.05
p<0.05
) Cur-NP-FA: ↑TNC; ↓ cell density;
ANG (CD31, CD34); ↑ pro-
flammatory response in the tumor
icroenvironment; p<0.05
) Cur-NP-HA ↓TV (~86%); Cur-





) Cur-NP-HA ↓TW (~75%);





















































Animal modela Treatment regimenb Dose; route Nanostructure platform
Laha et al. (31)/India
and USA




Metal organic frameworks NPs (IRMOF-3) with or
without folic acid (FA) [(Zn (NO3)2; NH2-H2BDC]
1
(~
4T1/mouse/ Every 5 days for 4 times Route of
administration:
(NM)
HD: 371,7 nm/PDI: 0.397 2
↓
(NM)/ ZP: −10.9 mV/EE: 98% 3
d
Mammary fat pad
Vakilinezhad et al. (32)/
Iran
Sprague Dawley rats/n =
6/
Four months after tumor
induction;




Once a week for 4 weeks Intravenous HD: 92.4 nm/PDI: 0.150
- Free Cur vehicle: aqueous
suspension
ZP: −5.12 mV/EE: 89.4%
Yuan et al. (33)/China Balb/c nude mice/n = 6/ TV of 100 mm3; 2.5 mg/kg; Polymeric NPs (mPEG- PLGA-Pglu) 1
MCF-7/human/ Every other day 4 times; total
18 d
Intravenous HD: 228.5 nm/PDI: (NM) 2
(3 x 106 cells)/ ZP: −23.8 mV/EE: 76.9% 3
(~
Right flank
Sahne et al. (34)/Iran Balb/c mice/n = 4/ TV of 50–100 mm3; 4 mg/kg; Graphene oxide NPs (GO NPs with CMC, PVP, PEG,
FA);
1
4T1/mouse/ Daily for a total 3 weeks Intravenous HD: ~60 nm/PDI: (NM) 2








Ji et al. (35)/China Balb/c mice/n = 5/ First day of treatment: (NM); 5 mg/kg; Nanocrystals NPs with or without HA 1
N
p
4T1/mouse/ Every 2 days for a total 10
days
Intravenous Cur-NP and HA-Cur-NP: HD: 101.4 and 161.9 nm/








TABLE 1 | Continued
Outcomes
Antitumor activity Toxicity analysis





2) Cur-NP ↓TW (~82%); free Cur: ↓TW
(~62%); p<0.05
p<0.05
3) Cur-NP ↑TNC and ↑TAP; ↓ANG
(CD31); ↓PROL (Ki-67); p<0.05
1) Cur-NP-GE11 and Cur-NP ↓TV




2) Cur-NP-GE11↓TW (~56%); Cur-NP
↓TW (~48%); free Cur: no TW↓;
p<0.05
p<0.05
3) Cur-NP-GE11and Cur-NP ↑TAP
1) Cur-NP-CS and Cur-NP ↓TV




1) Cur-NP-PEI-HA ↓TV (~50%); Free




2) Cur-NP-PEI-HA ↓TW (~70%); free






1) Cur-NP↓TV (~77%); free Cur: ↓TV
(~66%); p<0.05
No damage in the
liver and kidney;

















































Animal modela Treatment regimenb Dose; route Nanostructure platform
He et al. (36)/China Balb/c mice/n = 6/ TV of 100 mm3 5mg/kg; Polymeric micellar NPs [amphiphilic diblock
copolymer— mPEG-b-PLG (Se)-TP];
4T1/mouse/ Every 4 days, for 4 times;
total 21 days
Intravenous HD: 136 nm/PDI: 0.071
(1 x 106 cells)/ - Free Cur vehicle: (NM) ZP: (NM)/EE: ~ 68%
Subcutaneous on the
right back
Jin et al. (37)/China
and USA
Balb/c nude mice/n = 5/ 7 days after tumor induction; 5 mg/kg; Polymeric NPs with or without EGFR-targeting
peptides (GE11) (PLGA-PEG);
MCF-7/human/ Every 24 h for 20 times Intravenous HD: 210 nm/PDI: 0.112;
(1 x 107 cells)/ ZP: −22 mV/EE: 92.3
Subcutaneous on the
dorsal flank
- Free Cur vehicle: (NM)
Abd-Ellatef et al. (38)/
Italy and Egypt
Balb/c mice/n = 8/ TV of 50 mm3; 5 mg/kg; Solid lipid nanoparticles (SLN) with or without
chitosan (CS) coating (cholesterol; trilaurin, butyl
lactate, Epikuron®200, Cremophor®RH60, sodium
taurocholate, Pluronic® F68);
JC/mouse/ Thrice (on day 1st, 7th, 14th) Intravenous HD: < 200 nm/PDI: (NM)
(1 x 107 cells)/ - Free Cur vehicle:
10% v/v DMSO suspension
ZP: (NM)/EE: 70–75%
Mammary fat pad
Li et al. (39)/China Balb/c mice/n = 4/ Tumor diameter of 4 mm; 8 mg/kg; Mesoporous silica nanoparticles with hyaluronan
(MSN-HA) or polyethyleneimine-folic acid (MSN-PEI-
FA).
MDA-MB-231/human/ Every 3 days for a total of six
times
Intravenous HD: < 300 nm/PDI: (NM)/
(1 x 107 cells)/ - Free Cur vehicle: (NM) ZP: ~ −20 mV (MSN-HA);
~ +40 mV (MSN-PEI-FA)
Subcutaneous
Kundu et al. (40)/India Swiss albine mice/n = 6/ Ten days after induction; 10 mg/kg; Metal NPs [Zinc oxide nanoparticles (ZnO) with PBA];
Ehrlish ascites
carcinoma cells/
Alternate days for 14 days. Intravenous HD: 413.63 nm/PDI: (NM)
(1.0 x 107/ml) - Free Cur vehicle: (NM) ZP: −16.4 mV/EE: 27%
Left flank
TABLE 1 | Continued
Outcomes
Antitumor activity Toxicity analysis
r-NP ↓TV (~69%); Cur-NP-biotin
(~79%); free Cur: ↓TV (~32%);
05
no WL
r-NP ↓TW (~70%); Cur-NP-biotin
(~85%); free Cur: ↓TW (~25%);
05
p<0.05
r-NP and Cur-NP-biotin: ↑TNC
↑TAP; ↓ANG (CD31; VEGF; COX-
PROL (Ki-67); p<0.05
r-NP ↓TV (~58.5%, day 12); ↓TV
.9%, day 20); p<0.05
No WL
r-NP ↓TW (~22%, day 20);
05
p<0.05
r-NP-HA ↓TV (~43.8%, day 12);
(~24%, day 20); p<0.05
No WL
r-NP-HA ↓TW (~22%, day 20);
05
p<0.05
r-NP-HA ↓tumor cell density;
05
r-NP-10mg/Kg ↓TV (~61%);
NP-20mg/Kg ↓TV (~92%); p<0.05
(ND)
r-NP- AnxA2 ↓TV (~44.0%); Cur-
TV (~33.5%); p<0.05
No WL
r-NP- AnxA2 ↓TW (~53.0%);
NP ↓TW (~30%); p<0.05
p<0.05
r-NP- AnxA2 and Cur-NP:
; ↓ NFkb; ↓PROL (Ki-67);
05

















































Animal modela Treatment regimenb Dose; route Nanostructure platform
Lv et al. (41)/China Kunming (mice)/n = 6/ TV of 300 mm3; 10 mg/kg; Polymeric NPs (PEG-PCDA) with or without biotin; 1) C
↓TV
p<0
EMT6/mouse/ Daily for 9 days; total 14 days Intravenous PEG-PCDA and biotin-PEG-PCDA: HD: 94.2 and




(1.0 x 107/ml) - Free Cur vehicle: cremophor
EL: dehydrated alcohol (1:1,
v/v) and diluted with
physiological saline






Yang et al. (42)/China Balb/c nude mice/n = 5 TV of 200 mm3 10 mg/kg; Micelle NPs (triblock copolymer PPBV); 1) C
(~28
MCF-7/human/ Every other day for 5 times;
total 20 days
Intravenous HD: 6.7 nm/PDI: 0.117 2) C
p<0
(1 x 107 cells)/ ZP: −1.42 mV/EE: 68.5%
Subcutaneous on the
flank
- Free Cur vehicle: (NM)




MCF-7/human/ Every other day for 5 times;
total 20 days
Intravenous HD: 350 nm/PDI: (NM) 2) C
p<0




- Free Cur vehicle: (NM)
Greish et al. (44)/
Bahrain
Balb/c mice/n = 5/ TV of 100 mm3; 10 and 20 mg/
kg;
Micelles (curcumin–metal complex and SMA) 1) C
Cur-
4T1/mouse/ frequency of treatment:
unclear; total 10 days
Intravenous HD: 248 nm/PDI: 0.274;
(1 x 106 cells)/ ZP: −11 mV/EE: 80%
Bilaterally on the flanks
Mukerjee et al. (45)/
USA




MCF10CA1a/human/ Thrice week for a total 30
days
Intravenous Cur-NP and AnxA2-Cur-NP: HD: 150 and 157 nm/
PDI: ~0.240 and 0.200, respectively
2) C
Cur-








Balb/c nude mice/n = 5/ 8 days after induction; 20 mg/kg Polymeric NPs [PLGA/PVA with or without folate (F)] 1) C
(~75





























TABLE 1 | Continued
Outcomes
tform Antitumor activity Toxicity analysis
3) Cur-NP-F and Cur-NP ↓ cell density
without PAE) 1) Cur-NP-PAE ↓TV (~65.6%); Cur-NP
↓TV (~47.1%); p<0.05
no WL
2) Cur-NP-PAE ↓TW (~76%);
Cur-NP ↓TW (~53%); p<0.05
p<0.05
sensitive 1) Cur-NP ↓TV (~38%); p<0.05 ↓ Damage in
major organs
2) Cur-NP ↑ ST; no WL
3) Cur-NP ↑TNC and ↑TAP p<0.05
ition: not
)]
1) NP-40mg/Kg ↓TV (~72%); NP-
80mg/Kg ↓TV (~76%); p<0.05
no WL
2) NP-40mg/Kg ↓TV (~61%); NP-
80mg/Kg ↓TV (~64%); p<0.05
No change in food
intake and
behavior
3) NP ↑ ratio of M1/M2 macrophages p<0.05
thout folate (FA)
, castor oil, Tween
1) Cur-NP-FA ↓TV (~83%); Cur-NP
↓TV (~66%); free Cur: ↓TV (~31%);
No WL
p<0.05
e; CMC, carboxymethyl cellulose; CPC-SNEDDS, curcumin-phospholipid complex self-
or; FA, folic acid; HA, hyaluronic acid; MNU, N-methyl nitroso urea; mPEG-b-PLG (Se)-TP,
onjugated and a two-photon AIE fluorogen (TP) on the terminal group of PLG segments.;
rmined; (NM), not mentioned; NPs, nanoparticles; PAE, poly (b-aminoester; PBA, phenyl
-PBLA-PVIm triblock copolymer; PROL, tumor proliferation; PVA, polyvinyl alcohol; PVP,









































Animal modela Treatment regimenb Dose; route Nanostructure pla
(5 x 106 cells)/ ZP: −28.2 mV/EE: 68.6%
Right flank
Yu et al. (47)/China Balb/c nude mice/n = 5/ TV of 100–400 mm3; 40 mg/kg Micelles NPs (MPEG-PLA with or
MCF-7/human/ Every other day for 5 times for
a total 24 days
Intravenous HD: 128.4 nm to 171.0 nm/
PDI: 0.118 to 0.134
(3 x 106 cells)/ ZP: −2.0 to +4.0 mV/
EE: 96.5 to 98.8%
Subcutaneously right
flank
Huang et al. (48)/China Balb/c mice/n = 5/ TV of 40–50 mm3/ 50 mg/kg Polymeric NPs (HA-CHEMS); pH-
4T1/mouse/ Every 2 days for a total of 5
times
Intravenous HD: 144 nm/PDI: (NM);
(NM)/ ZP: −21.25 mV/EE: (NM)
Flank




Dendrosome NPs (DNC) [compos
mentioned (patent number: 7175
4T1/mouse/ daily for 35 consecutive days Route of
administration:
(NM)
HD; PD; ZP; EEI: (NM)
(1 x 106 cells)/
left flank
Lin et al. (50)/China Balb/c nude mice/n = 6/ First day of treatment: (NM)/ Dose: (NM)/ Lipid based NPs (NLC) with or w
coating (PEG-DSPE, soya lecithin
80, Precirol ATO-5);
MCF-7/human/ once every 3 days for 15
days
Intravenous HD: 126.8 nm/PDI: 0.16
(NM)/ ZP: +12.6 mV/EE: 82.7%
Subcutaneous in the
right armpit
- Free Cur vehicle: (NM)
aAnimal type/replicates/cell type injected/source/cell concentration/local of cell insertion;
bFirst day of treatment (or tumor volume)/treatment frequence and total experiment time; ANG, angiogenesis; CHEMS, cholesteryl hemisuccina
nanoemulsifying drug delivery systems; Cur, curcumin; d, days; DSPE, distearoyl phosphatidyl- ethanolamine; EGFR, epidermal growth factor recept
poly-(ethylene glycol)-b-poly(L-glutamic acid)-two-photon AIE fluorophores [mPEG-b-PLG (Se)-TP] amphiphilic copolymer with selenide group (Se)
MPEG-PCL, methoxypoly(ethylene glycol)-polycaprolactone; NF-kB, nuclear factor kappa b; NH2-H2BDC, 2-amino terephthalic acid; (ND), not det
boronic acid; PCDA, pentacosadiynoic acid; PEG, poly(ethylene glycol); PGlu, poly L-glutamic acid; PLA, polylactic-co-glycolic acid; PPBV, mPEG





Ombredane et al. Curcumin Nanoparticles in Breast Cancer Treatmentstudies, and 24 studies showed low risk of selection bias of
reported outcomes.
Synthesis of Results
A wide variety of NP types were used in the included studies.
Polymer NPs were mostly used for curcumin delivery (n = 9),
followed by micelles (n = 6), lipid-based NPs (n=3), metal NPs (n =
2), hybrid NPs (n=2), dendrosomal NP (n =1), nanocrystal (n=1),
graphene oxide NP (n=1), and mesoporous silica NP (n=1). Poly
(ethylene glycol) chains (PEG) were present in NP composition in
11 studies. Nine studies evaluated NPs associated with targeting
moieties such as folic acid (n=5), hyaluronic acid (n=1), EGF
peptides (n=2), and AnxA2 (n=1). With HD ranging from 101.4
to 371.7 nm, most Cur-NPs presented negative Zeta potential (−48
to +40 mV) (n=22) and EE% from 32 to 98% (Table 1).
Concerning experimental design, studies were heterogeneous
regarding animal model, route of administration, duration of the
experiment, and dose of treatment. Ten studies adopted nude
mice as animal models when tumor was induced with human
cells and another 16 used mice with a native immune system for
tumor induction with murine cells. One study used rats with
MNU-chemically induced mammary tumors (n=1). The main
human cell lines used were MCF-7 (n=6), MDA-MB-231 (n=3),
MDA-MD-468 (n=1), MCF10CA1a (n=1), and BT-549 (n=1).
The murine cell lines used were 4T1 (n=9), EMT6 (n=1), JC
(n=1), and Ehrlich ascites carcinoma cells (n=1). One study used
the transplantation of spontaneous mouse mammary tumor
pieces (n=1) as the breast cancer model. Implantation of tumorFrontiers in Oncology | www.frontiersin.org 11cells into the mammary fat comprised three studies, while the
others adopted subcutaneous implantation into the flank (n=14)
or armpit (n=1).
The first day of treatment was described according to days
after induction (n=9), ranging from 3 days to 4 months, or tumor
volume (n=13) in the range of 40 to 400 mm3. The curcumin
doses used in the treatments varied between 2 and 100 mg/Kg
and were administered daily (n=8), every other day (every 2
days) (n=7), three times a week (n=6); twice a week or less (n=4).
Intravenous administration was the main route of administration
used in the included studies (n=18). Few studies used intraperitoneal
(n=2), intratumoral (n=2), or oral administration route (n=1); and
one did not clearly mention this information (n=1).DISCUSSION
Summary of Evidence
The structure of curcumin has chemical groups that allow
interactions of diverse chemical natures (e.g., covalent, non-
covalent, hydrophobic, and hydrogen bonds) with molecules
involved in the different pathways of breast carcinogenesis (9,
16). It has been reported that curcumin inhibits cell proliferation,
tumor invasion, and angiogenesis. As an anti-proliferative agent,
curcumin induces cell cycle arrest and p53-dependent apoptosis.
It also alters signaling protein expression, such as Ras, protein
kinase B (Akt), and phosphatidylinositol-3-kinase (PI3K) (51).FIGURE 3 | Flow diagram of literature search and selection criteria adapted from PRISMA (18).March 2021 | Volume 11 | Article 612903
Ombredane et al. Curcumin Nanoparticles in Breast Cancer TreatmentAdditionally, the use of curcumin has been described as a
potential strategy for inhibiting EZH2 (enhancer of zeste
homolog-2), a histone modifier protein subunit involved in
tumor growth, metastatic potential, and in the regulation of
drug resistance. In breast cancer, it has been reported that
curcumin is able to inhibit the proliferation of human breast
cancer MDA-MB-435 cells in correlation with the downregulation
of EZH2 expression (52, 53).
Curcumin has demonstrated anti-invasive effects through
downregulation of matrix metalloproteinase (MMP-2) and
upregulation of tissue inhibitor of metalloproteinase (TIMP-1)
in MDA-MB-231 breast cancer cells (54). Interestingly, emerging
evidence indicates that the chemopreventive and chemotherapeutic
properties of curcumin are closely linked to the modulation of
miRNAs involved in tumorigenesis and metastasis signaling
pathways, e.g., hedgehog, notch-1, PI3K/Akt/mTOR, Wnt/b-
catenin, IGF, VEGF, and TGF-b/smad3 pathways (55, 56).
Gallardo et al. (57) demonstrated that curcumin prevents the
migration and invasion of breast cancer cells (MCF-10F and
MDA-MB-231) by targeting miR-34a as a regulator of Rho-A and
other genes involved in epithelial-mesenchymal transition, such as
Axl, Slug, and CD24 (57). Curcumin can also prevent angiogenesisFrontiers in Oncology | www.frontiersin.org 12by inhibiting vascular endothelial growth factor (VEGF) (58, 59)
and suppressing angiogenic cytokine interleukin-6 (60). All of the
mentioned mechanisms cited above along with anti-inflammatory
action and inhibition of cell growth factors, support confirmation of
the wide activity of curcumin in the regulation of tumor growth by
acting in different cancer hallmarks (9).
However, the hydrophobic property of curcumin limits its
applications and demonstrates less impressive success in clinical
trials (14). Additionally, free curcumin can undergo biomodifications
andmay be mostly excreted in feces or in bile in animal models (61).
Therefore, the use of drug delivery systems, such as NP platforms, is
an alternative to improve drug bioavailability, administer lower
doses, increase time of circulation, and enhance its biological
activity. The natural product-based nanomedicine field for cancer
treatment has increased and demonstrated great potential (6, 14).
The present systematic review reports the effects of Cur-NPs on
antitumoral activity and toxicity of in in vivomodels of breast cancer.
Analysis of the included studies showed that curcumin
evaluated in in vivo models of breast cancer has been loaded in
a wide variety of NP platforms, including different compositions,
sizes, and zeta potential. In fact, advantages were evidenced in all
the included studies that compared tumor volume reductionTABLE 2 | Overall quality of the selected studies. Detailed description of the evaluated parameters is found in Table S4.
Critical analysis of the articles included
Author Year Methodology Toxicity Outcomes Score Classification
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 %
Abd-Ellatef et al. (38) 2020 93 High quality
Alizadeh et al. (28) 2015 80 High quality
Chen et al. (26) 2017 93 High quality
Greish et al. (44) 2018 73 High quality
He et al. (36) 2019 86 High quality
Huang et al. (48) 2020 66 Moderate quality
Ji et al. (35) 2020 86 High quality
Jin et al. (37) 2017 86 High quality
Jung et al. (29) 2018 - - 86 High quality
Kundu et al. (40) 2019 80 High quality
Laha et al. (31) 2019 73 High quality
Li et al. (39) 2018 86 High quality
Lin et al. (50) 2016 80 High quality
Lv et al. (41) 2015 60 Moderate quality
Mahalunkar et al. (27) 2019 - - 86 High quality
Murkerjee et al. (45) 2016 - - 73 High quality
Mukhopadhyay et al. (46) 2020 80 High quality
Sahne et al. (34) 2019 93 High quality
Shiri et al. (49) 2015 - - 53 Moderate quality
Shukla et al. (25) 2017 86 High quality
Vaklinezhad et al. (32) 2019 - - 73 High quality
Wang et al. (30) 2018 - - 86 High quality
Yang et al. (42) 2017a 86 High quality
Yang et al. (43) 2017b 80 High quality
Yu et al. (47) 2014 80 High quality
Yuan et al. (33) 2018 86 High qualityMarch 2021 | Volume 11Yes No Unclear - Not evaluated.| Article 612903
Ombredane et al. Curcumin Nanoparticles in Breast Cancer Treatmentafter Cur-NP treatment with curcumin treatments in its free
form and/or with negative controls (Table 1). For instance, a
volume reduction of ~21% was observed in tumors of animals
treated with free curcumin, while a significant reduction of ~86%
was observed in animals treated with curcumin nanocrystals
coated with hyaluronic acid (35).
NPs are able to accumulate into solid tumors (e.g., breast cancer).
The classical concept states that NPs extravasate the tumor’s
vascular barrier through gaps between endothelial cells (owing to
irregular angiogenic growth) and are retained in the tumor mass
due to poor local lymphatic drainage—a passive process known as
the enhanced permeability and retention (EPR) effect (62, 63)
Nevertheless, this pathway has been currently under debate, and
updated data show evidence that it may not be the dominant
mechanism of NPs’ extravasation into solid tumors (64, 65). Other
mechanisms of NPs’ tumor accumulation have been investigated,
such as the trans-endothelial pathway, which is a metabolically
active process that requires endothelial cells to rearrange their
structure to present vesicles that can uptake NPs and further
deliver them to tumor cells nearby (64).Frontiers in Oncology | www.frontiersin.org 13Improvements in tumor NP accumulation and favorable
interaction between NPs and cancer cells can be obtained by
tailoring the surface of the NP with moieties able to confer
prolonged blood-circulation time (e.g., PEG) and specific active
targeting (e.g., ligands with affinity to molecules overexpressed in
tumor cells) (66). The main active targeting moieties found in the
included studies were folic acid (FA) and hyaluronic acid (HA).
FA shows affinity to folate receptors, which are tumor-associated
proteins overexpressed in more than 40% of human tumors,
including breast cancer (67). A metal organic framework of FA-
Cur-NPs significantly improved curcumin antitumor efficacy
(~61%), while non-modified NP accounted for ~44% for
tumor volume reduction (31). Similarly, attachment of HA, a
natural polysaccharide consisting of repeating disaccharide units,
to the surface of NPs, has been investigated since it binds to the
cell surface molecule CD44, a surface protein widely expressed in
breast cancer (68). Curcumin associated with HA-mesoporous
silica NPs showed a significant ~70% reduction in tumor weight,
while no significant effect was observed for free curcumin (39).
Other modifications of the curcumin-NP surface with ligandsTABLE 3 | Risk of bias in individual studies (SYRCLE’s Rob toll criteria). YES answers indicated low risk of bias, NO indicated high risk of bias, and UNCLEAR indicated
it was not possible to assign bias. Detailed description of the evaluated parameters is found in Table S3.
SYRCLE’s Risk of Bias
Author Year Selection Performance Detection Attrition Reporting Other
1 2 3 4 5 6 7 8 9 10
Abd-Ellatef et al. (38) 2020
Alizadeh et al. (28) 2015
Chen et al. (26) 2017
Greish et al. (44) 2018
He et al. (36) 2019
Huang et al. (48) 2020
Ji et al. (35) 2020
Jin et al. (37) 2017
Jung et al. (29) 2018
Kundu et al. (40) 2019
Laha et al. (31) 2019
Li et al. (39) 2018
Lin et al. (50) 2016
Lv et al. (41) 2015
Mahalunkar et al. (27) 2019
Murkerjee et al. (45) 2016
Mukhopadhyay et al. (46) 2020
Sahne et al. (34) 2019
Shiri et al. (49) 2015
Shukla et al. (25) 2017
Vaklinezhad et al. (32) 2019
Wang et al. (30) 2018
Yang et al. (42) 2017a
Yang et al. (43) 2017b
Yu et al. (47) 2014
Yuan et al. (33) 2018March 2021 | Volume 11 | Article 6Yes No Unclear - Not evaluated.12903
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have also been explored (29, 37, 45).
Once in the tumor site, NPs can be internalized by tumor cells
and/or release their cargo in the tumor microenvironment. It is
known that the tumor microenvironment is acidic (69), and this
pathological characteristic of cancer can be used as a strategy for the
controlled release of NPs responsive to acidic pH (40). This strategy
prevents cargo release to non-target tissues and aids in the
mitigation of possible adverse effects. Kundu and co-workers (40)
designed their study based on this approach by using pH-sensitive
NPs. They observed that the release of curcumin from the
nanohybrid zinc oxide NPs was improved in decreased pH and
resulted in an increased accumulation of curcumin in tumor tissue
and a significative tumor volume reduction (~77%). In addition, no
biochemical modifications or structural damage were observed in
the liver and kidneys (40). Huang and co-workers (48) encapsulated
curcumin in pH-sensitive polymeric NPs and showed a significant
reduction in tumor volume followed by increased survival time
(Table 1) (48). Internalization of NPs can be mediated or not by
active targeting ligands (depending on the mechanism triggered),
and it occurs mainly through endocytosis pathways where the
main mechanisms comprise a) clathrin-mediated endocytosis;
b) caveolae-mediated endocytosis, for NPs up to 200 nm;
c) macropinocytosis; and d) other clathrin and caveola-
independent endocytosis for NPs with sizes between 250 nm
and 3 µm (70, 71). Once inside the cells, NPs can interact with
specific organelles and/or release their cargo to reach potential
targets, such as the ones involved in cell death/survival and cell
proliferation pathways (66).
Curcumin can modulate multiple apoptosis signaling pathways.
The predominant apoptotic mechanism—extrinsic (receptor-
mediated) or intrinsic (mitochondrial) – differs between cell types,
differentiation stages, or curcumin concentrations. Increase of Bax/
Bcl-2 ratio, activation of caspase-3, inhibition of telomerase, DNA
fragmentation, and induction of redox signaling are some of the
apoptotic mechanisms activated by curcumin in distinct breast
cancer cells (72–74). Cell cycle arrest by free curcumin has also
been described and is potentially associated with its antiproliferative
effects (74). Regarding the antitumor mechanisms reported in the
included studies, Cur-NPs were shown to induce at least tumor
apoptosis, necrosis, and/or cell proliferation blockage in in vivo
breast cancer models (26, 28, 30, 34, 36, 37, 40, 41, 45, 48).
Angiogenesis involves the development of new blood vessels
from pre-existing vessels and plays an important role in tumor
growth, maintenance, and metastasis (26, 30). Free curcumin has
been described presenting anti-angiogenesis effects by inhibiting
or modulating many pro-angiogenesis factors such as vascular
endothelial growth factor (VEGF), matrix metalloproteinases
(MMPs), and basic fibroblast growth factor (bFGF) in in vitro
and in vivo studies (26, 30, 58). Similar effects were reported in
the included studies when curcumin was associated with
micelles, graphene oxide, or polymeric NPs and administered
in in vivo breast cancer models (28, 34, 36, 41, 45).
It is known that a population of cancer stem cells (CSCs) is
present within the tumor microenvironment. These cells are able
to activate self-sustaining and self-renewal mechanisms, givingFrontiers in Oncology | www.frontiersin.org 14rise to heterogeneous cancer cells that comprise the tumor (75).
CSCs are also known to present a high expression of P-
glycoprotein, a well-known protein involved in multidrug
resistance (MDR), making them less susceptible to antitumor
therapies (76). Interestingly, free curcumin has been described
affecting CSCs with no toxicity to normal stem cells. The
mechanisms involve modulation of P-glycoprotein (77);
suppression of the release of cytokines such as interleukin (IL)-
6, IL-8, and IL-1, which stimulate CSCs; among others (75). Cur-
NPs of the studies evaluated herein seems to maintain this
property since studies with curcumin associated with micelles
and polymeric NPs have shown a significant reduction in the
proportion of CSCs present in in vivo breast cancer models (26,
33) (Table 1).
Metastasis is the process where cells from the primary tumor
spread to distant sites and give rise to a secondary tumor.
Advanced breast cancer includes both stage (IV) of metastatic
breast cancer and inoperable locally advanced breast cancer, which
has not spread to distant organs. The most common site affected
by breast cancer cells are the axillary lymph nodes, lungs, liver, and
bones (1, 78). In the present review, Cur-NPs showed significant
effects against tumor metastasis in in vivo breast cancer models.
For instance, curcumin associated with graphene oxide NPs
reduced the regions of metastasis in a triple negative breast
cancer model (34).
Different routes of administration were adopted among the
studies evaluated herein. The oral administration route is
preferred over other routes for drugs and NPs due to advantages
such as ease of ingestion, good patient compliance, and pain
avoidance. The main limitation of this route is the knowledge of
the real dose absorbed (79). Only one included study explored oral
administration with curcumin entrapped in a lipid-based NP (25).
Interestingly, a remarkable tumor volume reduction of ~60% was
achieved; nevertheless, the dose of curcumin administered was the
highest among all the other studies (100 mg/Kg), probably due to
variations in NP absorption through this route.
Other routes of administration can be applied to avoid
the gastrointestinal tract and potential degradation (80).
Intratumoral administration is an interesting option for breast
cancer therapy. NPs can be administered with a minimal invasive
procedure with a regular biopsy needle, for example, right in the
tumor site, increasing the lifetime of drugs in contact with
malignant target cells, reducing adverse effects on healthy
tissues, and bypassing liver metabolism (81). Two of the
included studies used this route to administer micelle NPs to
triple negative breast cancer models and showed similar
outcomes in terms of tumor volume reduction (51–60%)
(26, 27).
The intraperitoneal (IP) route is commonly used in rodents
and consists of an injection of pharmacological drugs into the
peritoneal cavity. Quick and minimally stressful for animals, the
IP route permits safe administration of a large volume of drug
and it is more appropriate when the intravenous route is
challenging. The IP route is an entry portal for blood
circulation through the capillary system (80). Two of the
included studies reported the success of Cur-micelle NPMarch 2021 | Volume 11 | Article 612903
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~80 and ~59.1%, respectively (28, 29).
The intravenous (IV) route of administration enables the rapid
circulation of an administered drug in the bloodstream. Although
approximately 70% of the included studies adopted this route of
administration, precise efficacy comparisons regarding composition
and other characteristics (e.g., HD, PDI, PZ) of NPs are limited due
to variations in cell lines, number of cells used for induction,
moment of the first treatment, and dose/treatment regimens.
However, some comparisons involving dose concentrations and
presence of active targeting were possible when analyzing studies
that evaluated more than one experimental variable in the same
experimental design. In general, it was observed that all the types of
NPs used led to improved outcomes in terms of tumor volume
reduction in models of estrogen receptor (ER) positive, chemically
induced, and triple negative breast cancer (Table 1).
MCF-7 is one of the human cell lines most commonly used
for breast cancer research, since it expresses substantial levels of
estrogen receptor (ER) mimicking the majority of breast cancers
diagnosed nowadays (82). Analyzing MCF-7 models of the
included studies, it was observed that the influence of active
targeting in improved efficacy outcomes depends on the moiety
used. Lin and co-workers (50) reported significant improvements
in tumor volume reduction when attaching FA, as the targeting
moiety, to lipid-based NPs (~83%) when compared to non-
targeted NPs (~66%) (50). Similar results were observed in
MDA-MB-231 in vivo models (triple negative breast cancer),
where the presence of folate, as an active targeting moiety,
showed improved tumor volume reduction (~90%) when
compared to non-targeted NPs (~75%) (46). On the other
hand, no significant improvements were observed when
peptide moieties with affinity to EGFR were used in polymeric
NPs when compared with non-targeted NPs (37). Another
interesting aspect that seems to improve efficacy outcomes in
MCF-7 models is the design of pH-sensitive NPs. Yu and co-
workers (47) reported improved reduction of tumor volume in
animals treated with pH-sensitive micelles (mPEG-PLA with
PAE) (~65.6%) when compared to the ones treated with non-
pH-sensitive micelles (~47.1%) (47).
Both MCF-7 and MDA-MB-231 conventional in vivo models
are induced in immunocompromised mice due to the human
origin of these cell lines (83). These models, also known as
xenograft, lack relevance when the study aims to evaluate/
associate the outcomes with a functional immune system. In
this case, syngeneic models, where cells of the same genetic
background (murine) are implanted into a mouse with a native
immune system, are recommended (83). Syngeneic breast cancer
models usually use the 4T1 cell line as a representative model
that mimics triple negative breast cancers (84). Analyzing 4T1
models used in the included studies, it was observed that the
outcome of tumor volume reduction showed a tendency to
respond in a dose-dependent manner. Greish and co-workers
(44) showed that a 20mg/Kg dose led to improved tumor volume
reduction (~92%) when compared to a 10 mg/ml dose (~61%)
(44). Nevertheless, when comparing high doses, such as 40 and
80 mg/Kg, no significant improvements were observed betweenFrontiers in Oncology | www.frontiersin.org 15them (49). The presence of the active targeting moieties FA or
HA in the NPs showed improved efficacy, as reported by Laha
and co-workers (31) and Ji and co-workers (31, 35).
Analyzing only the studies of Sahne and co-workers (34), Ji
and co-workers (35) and He and co-workers (36), all with breast
cancer induction with 4T1 cells (106) in Balb/c mice, and with
the treatments performed intravenously and in very similar
doses, 4 or 5 mg/kg, but with a difference in the treatment
schedule (Table 1), (in the work of Sahne and co-workers, the
treatment was daily, for 21 days; in the work of Ji and co-workers,
the treatment was every two days for 10 days; and in the work of
He and co-workers, it was every four days in 21 total days), it can
be observed that, interestingly, the treatments with the Cur-NPs,
either by FA-GO-NP or HA-Cur-NP, promoted a similar
percentage of reduction in tumor volume (approximately 86%,
Table 1). Assessing NPs, HA-Cur-NP is a nanocrystal that has a
162 nm HD, while FA-GO-NP is a graphene oxide NP that has a
60 nm HD. In the treatment aspect, treatment every 2 days for
only 10 days of HA-Cur-NP had the same antitumor efficiency as
daily treatment for 21 days of FA-GO-NP. Therefore, it is a
shorter and less aggressive therapeutic regimen, presenting
similar efficiency (34–36).
The elimination of NPs occurs in organs and tissue systems after
i.v. injection by two main clearance systems: reticuloendothelial
system (RES) or mononuclear phagocyte system (MPS) and by
renal and hepatic systems. Properties of NPs, including core type,
surface chemistry, size, shape, degradability, and surface charge
influence the process of clearance (85). The MPS is based on
phagocytosis (mostly for NPs between 50 and 200 nm) or
pinocytosis, and degraded NPs are excreted into the blood
circulation, decreasing the injected dose (85, 86). Renal and
hepatic systems are the main clearance organs of NPs less than
100 nm through glomerular filtration and tubular secretion in the
kidney. NPs that are not cleared by the kidney can be processed in
the liver due to the presence of a large number of Kupffer cells
that can sequester foreign bodies, and the very permeable
sinusoidal endothelial cells that enhance liver uptake and
retention of NPs (85).
Among the included studies that evaluated toxicity effects,
none of the Cur-NPs provoked toxicity, considering biochemical
markers, hematological changes, damage to major organs, and
weight loss (Table 1). It is worth pointing out that the majority of
studies (~80%) analyzing the efficacy of Cur-NPs also evaluated
at least one toxicity outcome, showing that research into NPs is
not only interested in treatment efficacy but also considers safety
issues. Nevertheless, ~33% of such studies used only body weight
as a parameter for toxicity analysis. Thus, it is important to
pursue deeper investigations beyond these parameters in order to
understand better the safety of the treatment and enable its
clinical translation.LIMITATIONS
Some limitations were encountered during the elaboration of
this systematic review. First, there was high heterogeneityMarch 2021 | Volume 11 | Article 612903
Ombredane et al. Curcumin Nanoparticles in Breast Cancer Treatmentregarding NP type, characteristics of NPs, animal models, period
of administration, and intervention concentrations which
made meta‐analysis unfeasible. Furthermore, one study was
excluded in phase 2 because its full copy could not be
obtained. Moreover, most SYRCLE’ RoB criteria were unclearly
reported in most included studies therefore, limiting the
evaluation of study quality.CONCLUSION
This systematic review evidences that the use of NPs as drug
delivery systems for curcumin is a promising approach for the
treatment of breast cancer. The results show significant tumor
volume reduction in all breast cancer models, which could be
attributed to increased apoptosis and necrosis rate, reduction of
tumor cell proliferation and impairment of angiogenesis,
and even reduction of the population of stem cancer cells,
which might also be correlated with improved survival times.
All of these improved outcomes are also related to no or low
adverse effects in terms of body weight, histopathology of major
organs (e.g., liver, kidneys, lungs, spleen), or alterations in
hematological/biochemical parameters.
Variations in NP structure should be considered according to
the type of breast tumor as well as the route of administration
and dose schedule. In addition, the cost-effective and large-scale
manufacturing of the proposed NP platforms is also of
considerable importance to enable a real translation of these
remarkable technologies from the bench to the bedside.
Although Cur-NPs’ association with other therapeutic
approaches is not within the scope of the present work, it is
recommended that systematic evaluations of outcomes regarding
efficacy and toxicity of Cur-NPs when associated with
other plant-derived molecules or currently prescribed therapies
(e.g., chemotherapy, radiotherapy) should be further considered.
Altogether, this systematic review supports the proposal that
Cur-NPs provide an effective and safe therapeutic approach in in
vivo models of breast cancer, reinforcing the currently available
evidence that their usage should be further analyzed in clinical
trials for breast cancer treatments.Frontiers in Oncology | www.frontiersin.org 16DATA AVAILABILITY STATEMENT
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